Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 6.90%233.59B | 3.32%964.09B | -1.62%228.73B | 5.69%260.35B | 2.89%256.5B | 6.60%218.51B | 16.22%933.11B | 10.96%232.5B | 9.07%246.33B | 29.40%249.31B |
Cost of revenue | 4.54%192.08B | 4.24%798.02B | -4.00%192.96B | 7.58%211.92B | 6.12%209.4B | 7.92%183.73B | 15.29%765.59B | 14.76%201.01B | 8.15%196.99B | 24.23%197.33B |
Gross profit | 19.37%41.51B | -0.87%166.07B | 13.60%35.77B | -1.85%48.43B | -9.38%47.1B | 0.14%34.78B | 20.70%167.53B | -8.41%31.48B | 12.86%49.34B | 53.69%51.98B |
Operating expense | 7.97%40.29B | 9.28%146.36B | 13.42%36.64B | 10.48%38.48B | 0.38%33.92B | 13.09%37.31B | 29.29%133.93B | 19.45%32.31B | 31.99%34.84B | 42.22%33.8B |
Operating profit | 148.21%1.22B | -41.33%19.71B | -6.21%-872M | -31.44%9.94B | -27.51%13.18B | -246.68%-2.54B | -4.58%33.6B | -111.20%-821M | -16.28%14.5B | 80.78%18.18B |
Net non-operating interest income (expenses) | 1,323.08%185M | 277.89%708M | 3,685.71%265M | 253.06%375M | 207.84%55M | 111.93%13M | -111.70%-398M | 121.21%7M | -202.47%-245M | -537.50%-51M |
Non-operating interest income | 67.26%470M | 118.85%1.82B | 154.55%728M | 184.97%493M | 25.88%321M | 136.13%281M | 56.87%833M | 88.16%286M | 63.21%173M | 46.55%255M |
Non-operating interest expense | 6.34%285M | -9.42%1.12B | 65.95%463M | -71.77%118M | -13.07%266M | 17.54%268M | 71.21%1.23B | 50.81%279M | 123.53%418M | 68.13%306M |
Net investment income | -20.03%3.41B | 876.84%2.78B | 232.97%1.59B | 28.88%-3.51B | -37.34%433M | -25.48%4.27B | -94.42%285M | -130.31%-1.2B | -434.26%-4.94B | 268.95%691M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 141.20%267M | -374.59%-335M | 334.33%291M | 127.38%288M | -89.30%23M | -185.38%-648M | -60.26%122M | -83.25%67M | -2,123.08%-1.05B | |
Income from associates and other participating interests | -12.93%458M | -2.08%1.84B | -19.11%326M | -20.98%531M | -41.78%457M | 2,668.42%526M | 1,281.62%1.88B | 2,778.57%403M | 8,300.00%672M | 785M |
Special income (charges) | 60.26%-124M | -400.56%-39.98B | 49.26%-3.64B | -5,401.85%-35.6B | -548.48%-428M | -231.91%-312M | -163.60%-7.99B | -1,290.71%-7.18B | 60.76%-647M | 96.05%-66M |
Less:Other special charges | 127.36%29M | -85.84%266M | -88.20%134M | -111.32%-66M | 360.61%304M | -212.77%-106M | 642.69%1.88B | 174.64%1.14B | -61.77%583M | -58.23%66M |
Less:Write off | -77.27%95M | 550.20%39.71B | -41.94%3.51B | 55,623.44%35.66B | --124M | --418M | 119.95%6.11B | 557.67%6.04B | -48.39%64M | --0 |
Other non-operating income (expenses) | -409.38%-297M | 121.84%193M | -101.89%-7M | -103.59%-340M | 3,515.38%444M | 192.31%96M | -87.22%87M | -49.46%371M | -273.96%-167M | 79.37%-13M |
Income before tax | 134.15%4.86B | -153.99%-14.48B | 67.77%-2.67B | -406.31%-28.31B | -21.89%14.43B | -71.90%2.08B | -30.66%26.81B | -164.26%-8.3B | -47.41%9.24B | 128.94%18.48B |
Income tax | -1.33%4.31B | 8.65%15.03B | 420.78%6.69B | -124.34%-1.32B | 50.50%5.29B | 21.19%4.37B | 4.05%13.83B | -68.71%1.29B | 20.68%5.43B | 259.41%3.52B |
Net income | 123.99%550M | -327.34%-29.51B | 2.24%-9.37B | -807.50%-26.99B | -38.90%9.14B | -160.65%-2.29B | -48.85%12.98B | -208.83%-9.58B | -70.83%3.82B | 110.98%14.96B |
Net income continuous operations | 123.99%550M | -327.34%-29.51B | 2.24%-9.37B | -807.50%-26.99B | -38.90%9.14B | -160.63%-2.29B | -48.85%12.98B | -208.84%-9.58B | -70.82%3.82B | 110.95%14.96B |
Noncontrolling interests | 28.40%104M | -79.71%306M | -2.70%72M | -24.41%96M | -58.99%57M | -93.07%81M | -37.51%1.51B | -87.60%74M | -74.60%127M | -75.61%139M |
Net income attributable to the company | 118.74%445M | -359.93%-29.81B | 2.25%-9.44B | -834.26%-27.09B | -38.71%9.09B | -190.85%-2.37B | -50.04%11.47B | -217.66%-9.66B | -70.67%3.69B | 127.28%14.82B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 118.74%445M | -359.93%-29.81B | 2.25%-9.44B | -834.26%-27.09B | -38.71%9.09B | -190.85%-2.37B | -50.04%11.47B | -217.66%-9.66B | -70.67%3.69B | 127.28%14.82B |
Gross dividend payment | ||||||||||
Basic earnings per share | 118.79%2.17 | -360.07%-145.04 | 2.13%-45.91 | -832.93%-131.78 | -38.64%44.2 | -191.16%-11.55 | -49.68%55.77 | -218.46%-46.91 | -70.38%17.98 | 128.74%72.03 |
Diluted earnings per share | 118.79%2.17 | -360.11%-145.04 | 2.13%-45.91 | -832.93%-131.78 | -38.62%44.2 | -191.16%-11.55 | -49.67%55.76 | -218.49%-46.91 | -70.37%17.98 | 128.69%72.01 |
Dividend per share | 0 | -25.00%30 | -50.00%10 | 0 | 0.00%20 | 0 | 100.00%40 | 100.00%20 | 0 | 100.00%20 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |